Chinese Journal of Arteriosclerosis 2025;33(10):892-900

doi:10.20039/j.cnki.1007-3949.2025.10.009

The latest advances in targeting PCSK9 therapy in the cardiovascular field

Lin WANG 1 ; Xuan YANG ; Jinze FAN ; Jin'e WU ; Liuyi HAO

Affiliations

+expand

Keywords

low density lipoprotein cholesterol; proprotein convertase subtilisin/kexin type 9; proprotein conve-rtase subtilisin/kexin type 9 inhibitor; atherosclerosis; cardiovascular disease

Country

China

Language

Chinese

Abstract

Proprotein convertase subtilisin/kexin type 9(PCSK9)can modulate low density lipoprotein cholesterol(LDLC)levels,and its dysfunction is closely associated with the progression of atherosclerosis and cardiovascular diseases.Research has shown that PCSK9 inhibitors are highly effective in lowering lipids and have good safety and tolerability.New approaches to targeting PCSK9 inhibition are currently in different stages of clinical development.This review out-lines the primary mechanisms of PCSK9 and its impact on the cardiovascular system,emphasizing the current emerging strategies for targeting PCSK9 in lipid-lowering treatments.